Search

Your search keyword '"Gallo C."' showing total 128 results

Search Constraints

Start Over You searched for: Author "Gallo C." Remove constraint Author: "Gallo C." Publisher elsevier bv Remove constraint Publisher: elsevier bv
128 results on '"Gallo C."'

Search Results

1. OC.15.3: INCIDENCE AND CHARACTERISTICS OF ENDOSCOPIC GASTRIC POLYPS IN PATIENTS WITH AUTOIMMUNE ATROPHIC GASTRITIS: A MULTICENTRIC RETROSPECTIVE STUDY

5. Under-reporting of subjective symptoms and its prognostic value: a pooled analysis of 12 cancer clinical trials

6. Confirmatory validation analysis of the PROFFIT questionnaire to assess financial toxicity in cancer patients

7. (1192) Role of BAL Lymphocytosis and Blood Eosinophils in the Prediction of Acute Rejection in Lung Transplant Patients

12. A quantitative MRCP-derived score for medium-term outcome prediction in primary sclerosing cholangitis

14. PC.01.8 RADIOMICS-BASED MODEL FOR OUTCOME PREDICTION IN PRIMARY SCLEROSING CHOLANGITIS

16. Interrupted versus Continuous Suture for Bronchial Anastomosis in Lung Transplantation: Does It Matter?

17. Radiomics-based model for outcome prediction in primary sclerosing cholangitis

19. 157P Moderate physical activity (MPA) modulates immune system in breast cancer (BC) patients during preoperative chemotherapy: The NEO-RUNNER study

20. 1207O Bevacizumab + erlotinib vs erlotinib alone as first-line treatment of pts with EGFR mutated advanced non squamous NSCLC: Final analysis of the multicenter, randomized, phase III BEVERLY trial

21. 167P Chemotherapy-induced neutropenia and treatment efficacy in advanced non-small cell lung cancer (aNSCLC): A pooled analysis of 6 randomized trials

23. Carboplatin-based doublet plus bevacizumab beyond progression versus carboplatin-based doublet alone in patients with platinum-sensitive ovarian cancer: a randomised, phase 3 trial

28. Measuring financial toxicity of cancer in the Italian health care system: Initial results of the patient reported outcome for fighting financial toxicity of cancer project (proFFiT)

32. The HOBOE-2 multicenter randomized phase III trial in premenopausal patients with hormone-receptor positive early breast cancer comparing triptorelin plus either tamoxifen or letrozole or letrozole + zoledronic acid

33. Survival analysis of a multicentre, randomized phase 3 study on the optimization of the combination of bevacizumab with FOLFOX/OXXEL in patients with metastatic colorectal cancer (mCRC)

34. Quality-of-life analysis of the MITO-8, MaNGO, BGOG-Ov1, AGO-Ovar2.16, ENGOT-Ov1, GCIG study comparing platinum-based versus non-platinum-based chemotherapy in patients with partially platinum-sensitive recurrent ovarian cancer

40. Phase 3 randomized study of adjuvant anastrozole (A), exemestane (E) or letrozole (L) with or without tamoxifen (T) in postmenopausal women with hormone-responsive (HR) breast cancer. The FATA-GIM3 trial

41. Cisplatin in addition to single-agent first-line chemotherapy in elderly patients with advanced non-small-cell lung cancer (NSCLC): efficacy results of a joint analysis of the multicentre, randomized phase 3 MILES-3 and MILES-4 studies

42. Optimization of the combination of bevacizumab with FOLFOX/OXXEL in patients with metastatic colorectal cancer (mCRC): the multicentre, randomized phase 3 study OBELICS

43. A multicentre, randomized phase 3 study on the optimization of the combination of bevacizumab with mFOLFOX/OXXEL in patients with metastatic colorectal cancer (mCRC)

44. Effect on quality of life (QOL) of adding cisplatin to single-agent first-line chemotherapy in elderly patients with advanced non-small cell lung cancer (NSCLC): A joint analysis of the multicentre, randomized, phase 3 MILES-3 and MILES-4 studies

49. Acute kidney injury during colistin therapy: a prospective study in patients with extensively-drug resistant Acinetobacter baumannii infections

50. The association of financial difficulties with clinical outcomes in cancer patients: secondary analysis of 16 academic prospective clinical trials conducted in Italy

Catalog

Books, media, physical & digital resources